Comprehensive safety profile of dipeptidyl peptidase-4 inhibitors: a post-marketing study based on FAERS database using signal detection algorithms

Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) have acquired a foothold in managing type 2 diabetes mellitus, but few concerns have arisen regarding their overall safety profile. The aim of this study is to assess the potential risk of DPP-4 inhibitors by analyzing data from the FDA Adverse Ev...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Expert opinion on drug safety Ročník 24; číslo 12; s. 1 - 13
Hlavní autoři: Yoosuf, Beema T, Favas KT, Muhammed, Dutta, Pinaki, Bansal, Dipika
Médium: Journal Article
Jazyk:angličtina
Vydáno: England 23.04.2024
Témata:
Adverse Drug Reaction Reporting Systems - statistics & numerical data
Algorithms
Data Mining
Databases, Factual
Detection Algorithms
Diabetes Mellitus, Type 2 - drug therapy
Dipeptidyl-Peptidase IV Inhibitors - administration & dosage
Dipeptidyl-Peptidase IV Inhibitors - adverse effects
Humans
Hypoglycemic Agents - administration & dosage
Hypoglycemic Agents - adverse effects
Product Surveillance, Postmarketing
Retrospective Studies
United States
United States Food and Drug Administration
United States
Dipeptidyl peptidase-4 inhibitors
type 2 diabetes mellitus
signal detection
pharmacovigilance
signal detection algorithms
ISSN:1474-0338, 1744-764X, 1744-764X
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) have acquired a foothold in managing type 2 diabetes mellitus, but few concerns have arisen regarding their overall safety profile. The aim of this study is to assess the potential risk of DPP-4 inhibitors by analyzing data from the FDA Adverse Event Reporting System (FAERS) database. This is a retrospective study which explored the FAERS database till March 2023 for the collection of safety reports. The disproportionality analysis was performed using signal detection algorithms (SDAs) incorporating frequentist-based data mining approach such as relative reporting ratio (RRR), reporting odds ratio (ROR) and proportional reporting ratio (PRR) with 95% confidence interval (CI). A total of 14,573 adverse event reports were reported in the FAERS public dashboard associated with all the included DPP-4 inhibitors. The computed PRR, ROR, and RRR indicated positive signals for DPP-4 inhibitors with cardiac failure, pancreatitis, pemphigoid, hypoglycemia, acute kidney injury and lactic acidosis. Saxagliptin showed a higher signal score for cardiac failure, while sitagliptin was more associated with pancreatitis. Moreover, alogliptin exhibited an elevated signal score associated with pancreatic carcinoma. Several significant disproportionality signals were observed with DPP-4 inhibitors. However, clinicians have to consider the comorbidities and concomitant drugs while prescribing these drugs.
AbstractList Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) have acquired a foothold in managing type 2 diabetes mellitus, but few concerns have arisen regarding their overall safety profile. The aim of this study is to assess the potential risk of DPP-4 inhibitors by analyzing data from the FDA Adverse Event Reporting System (FAERS) database. This is a retrospective study which explored the FAERS database till March 2023 for the collection of safety reports. The disproportionality analysis was performed using signal detection algorithms (SDAs) incorporating frequentist-based data mining approach such as relative reporting ratio (RRR), reporting odds ratio (ROR) and proportional reporting ratio (PRR) with 95% confidence interval (CI). A total of 14,573 adverse event reports were reported in the FAERS public dashboard associated with all the included DPP-4 inhibitors. The computed PRR, ROR, and RRR indicated positive signals for DPP-4 inhibitors with cardiac failure, pancreatitis, pemphigoid, hypoglycemia, acute kidney injury and lactic acidosis. Saxagliptin showed a higher signal score for cardiac failure, while sitagliptin was more associated with pancreatitis. Moreover, alogliptin exhibited an elevated signal score associated with pancreatic carcinoma. Several significant disproportionality signals were observed with DPP-4 inhibitors. However, clinicians have to consider the comorbidities and concomitant drugs while prescribing these drugs.
Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) have acquired a foothold in managing type 2 diabetes mellitus, but few concerns have arisen regarding their overall safety profile. The aim of this study is to assess the potential risk of DPP-4 inhibitors by analyzing data from the FDA Adverse Event Reporting System (FAERS) database.BACKGROUNDDipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) have acquired a foothold in managing type 2 diabetes mellitus, but few concerns have arisen regarding their overall safety profile. The aim of this study is to assess the potential risk of DPP-4 inhibitors by analyzing data from the FDA Adverse Event Reporting System (FAERS) database.This is a retrospective study which explored the FAERS database till March 2023 for the collection of safety reports. The disproportionality analysis was performed using signal detection algorithms (SDAs) incorporating frequentist-based data mining approach such as relative reporting ratio (RRR), reporting odds ratio (ROR) and proportional reporting ratio (PRR) with 95% confidence interval (CI).RESEARCH DESIGN AND METHODSThis is a retrospective study which explored the FAERS database till March 2023 for the collection of safety reports. The disproportionality analysis was performed using signal detection algorithms (SDAs) incorporating frequentist-based data mining approach such as relative reporting ratio (RRR), reporting odds ratio (ROR) and proportional reporting ratio (PRR) with 95% confidence interval (CI).A total of 14,573 adverse event reports were reported in the FAERS public dashboard associated with all the included DPP-4 inhibitors. The computed PRR, ROR, and RRR indicated positive signals for DPP-4 inhibitors with cardiac failure, pancreatitis, pemphigoid, hypoglycemia, acute kidney injury and lactic acidosis. Saxagliptin showed a higher signal score for cardiac failure, while sitagliptin was more associated with pancreatitis. Moreover, alogliptin exhibited an elevated signal score associated with pancreatic carcinoma.RESULTSA total of 14,573 adverse event reports were reported in the FAERS public dashboard associated with all the included DPP-4 inhibitors. The computed PRR, ROR, and RRR indicated positive signals for DPP-4 inhibitors with cardiac failure, pancreatitis, pemphigoid, hypoglycemia, acute kidney injury and lactic acidosis. Saxagliptin showed a higher signal score for cardiac failure, while sitagliptin was more associated with pancreatitis. Moreover, alogliptin exhibited an elevated signal score associated with pancreatic carcinoma.Several significant disproportionality signals were observed with DPP-4 inhibitors. However, clinicians have to consider the comorbidities and concomitant drugs while prescribing these drugs.CONCLUSIONSeveral significant disproportionality signals were observed with DPP-4 inhibitors. However, clinicians have to consider the comorbidities and concomitant drugs while prescribing these drugs.
Author Dutta, Pinaki
Favas KT, Muhammed
Yoosuf, Beema T
Bansal, Dipika
Author_xml – sequence: 1
  givenname: Beema T
  orcidid: 0009-0001-3584-6212
  surname: Yoosuf
  fullname: Yoosuf, Beema T
  organization: Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research, Mohali, Punjab, India
– sequence: 2
  givenname: Muhammed
  orcidid: 0000-0001-8068-6839
  surname: Favas KT
  fullname: Favas KT, Muhammed
  organization: Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research, Mohali, Punjab, India
– sequence: 3
  givenname: Pinaki
  surname: Dutta
  fullname: Dutta, Pinaki
  organization: Department of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
– sequence: 4
  givenname: Dipika
  orcidid: 0000-0003-4520-3293
  surname: Bansal
  fullname: Bansal, Dipika
  organization: Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research, Mohali, Punjab, India
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38626310$$D View this record in MEDLINE/PubMed
BookMark eNp9kctuFDEQRS0URB7wCSAv2fRgt92PgVU0SgApEhIPiZ1VdpdnDN3txnZHmu_ID8fNzGyyyKpKpXOrdOtekrPRj0jIW85WnLXsA5eNZEK0q5KVclUKKRivXpAL3khZNLX8fZb7zBQLdE4uY_zDWFlXjXhFzkVbl7Xg7II8bPwwBdzhGN090ggW055OwVvXI_WWdm7CKblu39NDAxELSd24c9olH-JHCnTyMRUDhL-Y3LilMc3dnupMdtSP9Pb65vsP2kGCZUTn-J9x2xF62mFCk1ymoN_64NJuiK_JSwt9xDfHekV-3d783Hwp7r59_rq5viuMYOtU1OvSgmhbwSxDzSqwAuq2zt50A8YCFxp1DWi44a2R2nSWc2wt41yaaq3FFXl_2Jvt_psxJjW4aLDvYUQ_RyVY_nDJGy4z-u6IznrATk3BZbt7dXpkBj4dABN8jAGtMi7BYiwFcL3iTC2xqVNsaolNHWPL6uqJ-nTged0jf1OdNw
CitedBy_id crossref_primary_10_1007_s12020_025_04393_7
crossref_primary_10_1038_s41598_024_83014_1
crossref_primary_10_1186_s43088_025_00601_5
crossref_primary_10_1016_j_ejphar_2025_178113
Cites_doi 10.1185/030079906X162746
10.2337/diabetes.54.10.2988
10.1016/j.diabres.2016.11.010
10.1007/0-387-32824-6_5
10.1158/2767-9764.CRC-21-0042
10.1016/j.jjcc.2018.07.004
10.2337/dc15-0764
10.1016/j.jcjd.2016.09.003
10.1038/s41598-017-19055-6
10.1056/NEJMoa1307684
10.2337/dc16-1135
10.1111/j.1753-0407.2011.00143.x
10.1038/s41598-022-17366-x
10.7759/cureus.6812
10.1001/jama.2018.18269
10.2337/diaclin.34.1.3
10.1177/2042098619865413
10.1007/s00296-013-2710-7
10.1080/14740338.2019.1668373
10.1186/s12933-017-0648-x
10.1111/dom.12176
10.1038/s41598-022-27301-9
10.4103/2230-8210.141319
10.2169/internalmedicine.51.7592
10.1007/s13300-018-0408-2
10.1016/j.diabet.2017.05.013
10.1016/j.diabres.2015.05.025
10.1038/s41574-020-0399-8
10.2337/dcS15-3009
10.1016/j.pharmthera.2020.107503
10.4155/fmc.14.39
10.1007/s00592-013-0544-0
10.1016/j.pan.2015.05.465
10.1186/s40360-020-00447-w
10.1056/NEJMoa1305889
10.1016/S0140-6736(19)32131-2
10.1007/s40257-021-00625-4
ContentType Journal Article
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1080/14740338.2024.2343015
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Public Health
Pharmacy, Therapeutics, & Pharmacology
EISSN 1744-764X
EndPage 13
ExternalDocumentID 38626310
10_1080_14740338_2024_2343015
Genre Journal Article
GeographicLocations United States
GeographicLocations_xml – name: United States
GroupedDBID ---
00X
03L
0R~
29G
4.4
53G
5GY
AAMIU
AAOUU
AAYXX
ABEIZ
ABJNI
ABLIJ
ABLKL
ABXYU
ACGFS
ACIEZ
ADCVX
ADRBQ
AECIN
AENEX
AEOZL
AFRVT
AGDLA
AGMLL
AIJEM
AIRBT
AIYSM
AIZAD
AKBVH
ALMA_UNASSIGNED_HOLDINGS
ALQZU
BABNJ
BLEHA
CCCUG
CITATION
CS3
DKSSO
DU5
EBS
EMOBN
F5P
H13
HZ~
KRBQP
KSSTO
KUULJ
KWAYT
KYCEM
LJTGL
M4Z
MK0
O9-
P2P
RNANH
TASJS
TBQAZ
TDBHL
TERGH
TFDNU
TFL
TFW
TUROJ
TZHSB
V1S
~1N
0VX
AAPWH
ABBAB
ABJYH
ADTOD
AGMHR
AIHVM
CAZVN
CGR
CUY
CVF
DASJU
DAWQK
ECM
EIF
EJD
M44
NPM
7X8
ID FETCH-LOGICAL-c309t-692fa38830f0eb05af3a686386b7acfa13beb6aec1c18c4bcdf11e8f0114c59b3
ISICitedReferencesCount 6
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001206873500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1474-0338
1744-764X
IngestDate Thu Oct 02 12:13:01 EDT 2025
Wed Dec 10 14:04:40 EST 2025
Sat Nov 29 06:28:07 EST 2025
Tue Nov 18 21:50:05 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 12
Keywords Dipeptidyl peptidase-4 inhibitors
type 2 diabetes mellitus
signal detection
pharmacovigilance
signal detection algorithms
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c309t-692fa38830f0eb05af3a686386b7acfa13beb6aec1c18c4bcdf11e8f0114c59b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0003-4520-3293
0009-0001-3584-6212
0000-0001-8068-6839
PMID 38626310
PQID 3040321714
PQPubID 23479
PageCount 13
ParticipantIDs proquest_miscellaneous_3040321714
pubmed_primary_38626310
crossref_citationtrail_10_1080_14740338_2024_2343015
crossref_primary_10_1080_14740338_2024_2343015
PublicationCentury 2000
PublicationDate 20240423
PublicationDateYYYYMMDD 2024-04-23
PublicationDate_xml – month: 04
  year: 2024
  text: 20240423
  day: 23
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Expert opinion on drug safety
PublicationTitleAlternate Expert Opin Drug Saf
PublicationYear 2024
References e_1_3_6_30_1
e_1_3_6_31_1
e_1_3_6_32_1
e_1_3_6_33_1
e_1_3_6_11_1
e_1_3_6_10_1
e_1_3_6_15_1
e_1_3_6_38_1
e_1_3_6_14_1
e_1_3_6_39_1
e_1_3_6_13_1
e_1_3_6_12_1
e_1_3_6_19_1
e_1_3_6_34_1
e_1_3_6_18_1
e_1_3_6_35_1
e_1_3_6_17_1
e_1_3_6_36_1
e_1_3_6_16_1
e_1_3_6_37_1
e_1_3_6_42_1
e_1_3_6_20_1
e_1_3_6_41_1
e_1_3_6_21_1
e_1_3_6_44_1
e_1_3_6_22_1
e_1_3_6_43_1
e_1_3_6_2_1
e_1_3_6_40_1
e_1_3_6_6_1
e_1_3_6_5_1
e_1_3_6_4_1
e_1_3_6_3_1
e_1_3_6_9_1
e_1_3_6_8_1
e_1_3_6_7_1
e_1_3_6_27_1
e_1_3_6_28_1
e_1_3_6_29_1
e_1_3_6_23_1
e_1_3_6_24_1
e_1_3_6_45_1
e_1_3_6_25_1
e_1_3_6_26_1
References_xml – ident: e_1_3_6_27_1
  doi: 10.1185/030079906X162746
– ident: e_1_3_6_44_1
  doi: 10.2337/diabetes.54.10.2988
– ident: e_1_3_6_10_1
– ident: e_1_3_6_12_1
  doi: 10.1016/j.diabres.2016.11.010
– ident: e_1_3_6_16_1
– ident: e_1_3_6_43_1
  doi: 10.1007/0-387-32824-6_5
– ident: e_1_3_6_41_1
  doi: 10.1158/2767-9764.CRC-21-0042
– ident: e_1_3_6_31_1
  doi: 10.1016/j.jjcc.2018.07.004
– ident: e_1_3_6_30_1
  doi: 10.2337/dc15-0764
– ident: e_1_3_6_8_1
  doi: 10.1016/j.jcjd.2016.09.003
– ident: e_1_3_6_24_1
– ident: e_1_3_6_39_1
  doi: 10.1038/s41598-017-19055-6
– ident: e_1_3_6_13_1
  doi: 10.1056/NEJMoa1307684
– ident: e_1_3_6_29_1
  doi: 10.2337/dc16-1135
– ident: e_1_3_6_7_1
  doi: 10.1111/j.1753-0407.2011.00143.x
– ident: e_1_3_6_19_1
  doi: 10.1038/s41598-022-17366-x
– ident: e_1_3_6_26_1
  doi: 10.7759/cureus.6812
– ident: e_1_3_6_28_1
  doi: 10.1001/jama.2018.18269
– ident: e_1_3_6_9_1
  doi: 10.2337/diaclin.34.1.3
– ident: e_1_3_6_17_1
  doi: 10.1177/2042098619865413
– ident: e_1_3_6_35_1
  doi: 10.1007/s00296-013-2710-7
– ident: e_1_3_6_21_1
  doi: 10.1080/14740338.2019.1668373
– ident: e_1_3_6_33_1
  doi: 10.1186/s12933-017-0648-x
– ident: e_1_3_6_40_1
  doi: 10.1111/dom.12176
– ident: e_1_3_6_15_1
– ident: e_1_3_6_23_1
– ident: e_1_3_6_11_1
  doi: 10.1038/s41598-022-27301-9
– ident: e_1_3_6_6_1
  doi: 10.4103/2230-8210.141319
– ident: e_1_3_6_36_1
  doi: 10.2169/internalmedicine.51.7592
– ident: e_1_3_6_20_1
  doi: 10.1007/s13300-018-0408-2
– ident: e_1_3_6_37_1
  doi: 10.1016/j.diabet.2017.05.013
– ident: e_1_3_6_3_1
  doi: 10.1016/j.diabres.2015.05.025
– ident: e_1_3_6_25_1
– ident: e_1_3_6_2_1
  doi: 10.1038/s41574-020-0399-8
– ident: e_1_3_6_32_1
  doi: 10.2337/dcS15-3009
– ident: e_1_3_6_34_1
  doi: 10.1016/j.pharmthera.2020.107503
– ident: e_1_3_6_22_1
– ident: e_1_3_6_5_1
  doi: 10.4155/fmc.14.39
– ident: e_1_3_6_45_1
  doi: 10.1007/s00592-013-0544-0
– ident: e_1_3_6_4_1
  doi: 10.1016/j.pan.2015.05.465
– ident: e_1_3_6_18_1
  doi: 10.1186/s40360-020-00447-w
– ident: e_1_3_6_14_1
  doi: 10.1056/NEJMoa1305889
– ident: e_1_3_6_38_1
  doi: 10.1016/S0140-6736(19)32131-2
– ident: e_1_3_6_42_1
  doi: 10.1007/s40257-021-00625-4
SSID ssj0026573
Score 2.4047706
Snippet Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) have acquired a foothold in managing type 2 diabetes mellitus, but few concerns have arisen regarding...
SourceID proquest
pubmed
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 1
SubjectTerms Adverse Drug Reaction Reporting Systems - statistics & numerical data
Algorithms
Data Mining
Databases, Factual
Detection Algorithms
Diabetes Mellitus, Type 2 - drug therapy
Dipeptidyl-Peptidase IV Inhibitors - administration & dosage
Dipeptidyl-Peptidase IV Inhibitors - adverse effects
Humans
Hypoglycemic Agents - administration & dosage
Hypoglycemic Agents - adverse effects
Product Surveillance, Postmarketing
Retrospective Studies
United States
United States Food and Drug Administration
Title Comprehensive safety profile of dipeptidyl peptidase-4 inhibitors: a post-marketing study based on FAERS database using signal detection algorithms
URI https://www.ncbi.nlm.nih.gov/pubmed/38626310
https://www.proquest.com/docview/3040321714
Volume 24
WOSCitedRecordID wos001206873500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAWR
  databaseName: Taylor & Francis Journals Complete
  customDbUrl:
  eissn: 1744-764X
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0026573
  issn: 1474-0338
  databaseCode: TFW
  dateStart: 20020501
  isFulltext: true
  titleUrlDefault: https://www.tandfonline.com
  providerName: Taylor & Francis
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLa6gdAkhGDcymUyEtpLlhLXTuPwNhAVEtLUhyL6VtmpvQa6pErSav0d_CL-Gcd20rTSJuCBlyjKter35fgc-zvnIPSWJEmkA6F9KQnzWSSpLwOuffjuSCLigKtI22YT0cUFn0ziUafzq8mFWS-iLOPX1_Hyv0INxwBskzr7D3BvHwoHYB9Ahy3ADtu_At584YWa18L0UmgjyqxbcxvXcJYujZJltll4bgfGMZ95aTZPZWp677j852VeQkjc5ES7MrSeGfNmZn1heG5SE4y81BzyVnbGwWhBzJqPqlTdgHxxmRdpNa8ron_fyv5UUXkmU8t6q5k3K1aX9S9trVBermzByA9KXYlWyz0Ua1F6X5zKZDU3E--z1huvnDM8SjPwjNtZ2qy0fQ3AwC_TH2J3pqNvBTIuGbmnnHWOGAMWOUlnY75dCnZD0_6OMQbnltw4SjhZJWERCyBC75l39fqUga0Ld6-Hv3t5ZVlCTdxHa_3tfnnu5tQButOPwtioCsfDb9uYfxBGtEkc48G7G995hO41T9n3jm4JeazrM36IHtQxCz53XHuEOio7RqcjV_R8c4bHbQ5feYZP8agth745RvfdzDB2CW-P0c89gmIHO64JinONW4LiHYLilqDvscD79MSWntjSE-cZtvTEDT2xpSd29MRbeuKWnk_Q1-Gn8cfPft0axE9oEFf-IO5rQTmngQ6UDEKhqRhwGEsGMhKJFoRKJQdCJSQhPGEymWlCFNcm_E_CWNKn6DDLM_Uc4UDANaEMFLiLLGCac0CRScY00E3JuItYA8k0qevmm_Ytiympy-s2oE4NqNMa1C7qbW9busIxf7rhTYP3FEy8WbcTmcpX5ZTCQEv7JCKsi545Imwf2RDnxa1nXqKj9mN6hQ6rYqVeo7vJukrL4gQdRBN-Yjn7G8rDzdw
linkProvider Taylor & Francis
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comprehensive+safety+profile+of+dipeptidyl+peptidase-4+inhibitors%3A+a+post-marketing+study+based+on+FAERS+database+using+signal+detection+algorithms&rft.jtitle=Expert+opinion+on+drug+safety&rft.au=Yoosuf%2C+Beema+T&rft.au=Favas+Kt%2C+Muhammed&rft.au=Dutta%2C+Pinaki&rft.au=Bansal%2C+Dipika&rft.date=2024-04-23&rft.eissn=1744-764X&rft.volume=24&rft.issue=12&rft.spage=1391&rft_id=info:doi/10.1080%2F14740338.2024.2343015&rft_id=info%3Apmid%2F38626310&rft.externalDocID=38626310
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1474-0338&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1474-0338&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1474-0338&client=summon